Phase II study of cetuximab plus irinotecan for unresectable colorectal cancer

ABSTRACT: Interventions: cetuximab plus irinotecan Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Advaned Or Recurrent Colorectal Cancer

PROVIDER: 2617326 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR